Merck’s Covid-19 pill Molnupiravir only 30% effective in final analysis

Deaths, Healthcare, Hospitalization, Infection, Molnupiravir, Treatment, Vaccine

The pharmaceutical company Merck said on Friday that in a final analysis of a clinical trial, its antiviral pill molnupiravir reduced the risk of hospitalization and death among high-risk Covid patients by 30 percent, down from an earlier estimate of 50 percent.

The lower efficacy is a disappointment for the drug, known as molnupiravir, which health officials around the world are counting on as a critical tool to save lives and reduce the burden on hospitals. It increases the importance of a similar, apparently more effective, offering from Pfizer that is also under review by the Food and Drug Administration. report


The dangers of new oral Covid drug Molnupiravir


Image by Mahmoud Ahmed from Pixabay

** This post was originally published on November 27, 2021 **